Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;36(6):1651-1652.
doi: 10.1007/s00467-021-04981-5. Epub 2021 Feb 18.

Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome

Alan Majeranowski  1 , Marcin Okrój  2
Affiliations
Comment

Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome

Alan Majeranowski et al. Pediatr Nephrol. 2021 Jun.
No abstract available

PubMed Disclaimer

Comment in

  • Response to Majeranowski.
    Dossier C, Hogan J. Dossier C, et al. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10. Pediatr Nephrol. 2021. PMID: 33693991 No abstract available.

Comment on

References

    1. Dossier C, Prim B, Moreau C, Kwon T, Maisin A, Nathanson S, De Gennes C, Barsotti K, Bourrassi A, Hogan J, Deschênes G (2020) A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04811-0
    1. Said R, Tsimberidou AM (2017) Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther 17:1463–1470 - PubMed - PMC
    1. Tam C, Kuss B, Opat S, Boulos J, Marlton P (2017) Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Intern Med J 47(Suppl 4):5–10 - DOI

LinkOut - more resources